Core One Labs Inc. has Filed a Trademark Application with WIPO Madrid for an Additional Trademark

VANCOUVER, British Columbia, Dec. 3, 2019 /CNW/ -- Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) ("COOL" or the "Company") announces that it has filed a Trademark Application with WIPO Madrid to trademark "CBDSTRIPS" in the United Kingdom, Germany and Spain. This is in addition to its CannaStrips^™ filings.

The filing of additional Trademarks by Core One Labs Inc. is intended to protect future brands and products in Europe as part of the Company's anticipated market expansion into Europe. The specific countries identified in the application are the United Kingdom, Germany and Spain, which were determined to be the most viable countries for distribution of COOL products. Although the Company currently does not have the ability to distribute outside of California, the protection of its brands and technology throughout the world opens up many other possible relationships for COOL products in joint ventures or licensing agreements. The Company has future worldwide expectations for COOL products and the CannaStrips^™ brand.

CEO of Core One Labs Inc., Brad Eckenweiler, stated, "The foundations that we are securing outside of California will benefit the Company for years to come. We must always be building for the future and looking forward to identify opportunities and innovations supporting the Company's business model and its goals."

The Company will continue to update the market on other developments as they become available.

About CannaStrips^™

CannaStrips^™ is a formulated oral strip for effective buccal mucosal delivery that disrupts the barrier created by saliva coating the mucosal membrane for the active materials (in this case cannabinoids) which have been nanoparticulated and encapsulated to penetrate the multiple layers of mucosal and sub-mucosal membranes to the blood stream.  Once in the blood stream the encapsulation is undetectable as a foreign material by the liver. This un-detectability allows the material to avoid being filtered out of the blood stream by the liver. The encapsulation also is more effective in penetrating the blood-brain barrier and allowing for greater bioavailability and extending the effective time from a single dose.

About Core One Labs Inc.

Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product.  From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective. In addition, through its efforts to develop a better CannaStrips™ product, the Company has developed considerable expertise in cannabis extraction and nursery activities.  The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.

Core One Labs Inc.
Brad Eckenweiler
CEO & Director

FOR MORE INFORMATION, PLEASE CONTACT:
[email protected]
1-866-347-5058

Cautionary Disclaimer Statement:

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970.  Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect.  Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, The Company undertakes no obligation to publicly update or revise forward-looking information.

SOURCE Core One Labs Inc.